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The objective of this study was to develop a high-fidelity prototype for delivering multi-gene
sequencing panel (GS) reports to clinicians that simulates the user experience of a final
application. The delivery and use of GS reports can occur within complex and high-paced
healthcare environments. We employ a user-centered software design approach in a focus group
setting in order to facilitate gathering rich contextual information from a diverse group of
stakeholders potentially impacted by the delivery of GS reports relevant to two precision medicine
programs at the University of Maryland Medical Center. Responses from focus group sessions
were transcribed, coded and analyzed by two team members. Notification mechanisms and
information resources preferred by participants from our first phase of focus groups were
incorporated into scenarios and the design of a software prototype for delivering GS reports. The
goal of our second phase of focus group, to gain input on the prototype software design, was
accomplished through conducting task walkthroughs with GS reporting scenarios. Preferences for
notification, content and consultation from genetics specialists appeared to depend upon
familiarity with scenarios for ordering and delivering GS reports. Despite familiarity with some
aspects of the scenarios we proposed, many of our participants agreed that they would likely seek
consultation from a genetics specialist after viewing the test reports. In addition, participants
offered design and content recommendations. Findings illustrated a need to support customized
notification approaches, user-specific information, and access to genetics specialists with GS
reports. These design principles can be incorporated into software applications that deliver GS
reports. Our user-centered approach to conduct this assessment and the specific input we received
from clinicians may also be relevant to others working on similar projects.

Keywords

Author Manuscript

Genomic sequencing; Precision medicine; Genomic medicine; User experience research; Task
walkthroughs

1. Introduction

Author Manuscript

Customizing healthcare based on each person's unique genetic makeup could enable an era
of precision medicine that would improve prevention, diagnosis and treatment for many
types of health conditions. Routine precision medicine is rapidly approaching due to
increased use of whole genome, whole exome, and other types of multi-gene next generation
sequencing panels, hereafter referred to as genomic sequencing (GS). Results from GS will
be used more often as cost goes down and evidence of clinical utility increases [1,2]. With
the overwhelming amounts of data that can be generated from GS, the laborious task of
manually prioritizing clinically significant results often falls to clinical and laboratory
geneticists [3]. With the anticipated increase in the use of GS, manual review of genetic data
by clinicians, however, is not scalable. We believe that developing computerized tools to
help non-genetics experts make sense of GS results will greatly increase the likelihood of
achieving the vision of successful use of these data.
The healthcare environment in which such computerized tools might be deployed can be
complex and high-paced. Thus, there is a need to use a design methodology that aims to
support the current way of working. The primary objective of this study was to develop a
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high-fidelity prototype for delivering GS reports to clinicians that simulates the user
experience of a final application. Target stakeholders were clinicians involved in two
University of Maryland Program for Personalized and Genomic Medicine (PPGM)
initiatives that are exemplary use cases for precision medicine programs more broadly.
These initiatives are the Translational Pharmacogenetics Program (TPP) and the
Personalized Diabetes Medicine Program (PDMP). The TPP project aims to use a patient's
CYP2C19 genotype results to tailor antiplatelet therapy after a cardiac stent has been placed
[4]. The PDMP is designed to implement, disseminate and evaluate an approach to
identifying and genomically diagnosing highly penetrant genetic forms of diabetes. The goal
for PDMP is to enable personalized treatment for better and potentially less invasive glucose
control, prognosis, and assessment of familial risk for patients [5,6].

Author Manuscript

We employed a user-centered software design approach in a focus group setting in order to
facilitate gathering rich contextual information with a diverse group of stakeholders
potentially impacted by the delivery of GS reports relevant to the TPP and PDMP projects.
We completed two studies: The goal for the first study (phase 1) was to understand current
genetic and laboratory testing processes for documenting results, notifying clinicians of
those results, and viewing the results. Findings from the first study were used to propose the
design of software, which we called the Genomic Medicine Assistant (GMA), for delivering
GS reports to clinicians. In particular, we proposed a design that would potentially mitigate
issues with the reporting and notification processes we identified in phase 1. The goal for the
second study (phase 2) was to gather feedback on a proposed design of the GMA software
including preferences for interactions with, content contained in and the perceived usability
of the design.

Author Manuscript

2. Background

Author Manuscript

Much of the research surrounding the delivery of individual GS results to date has been
regarding the ethical, legal and social implications for communicating findings to patients
[7–9]. Indeed, GS technology is not mature and appropriate in all clinical scenarios and
there is the potential for cascade effects (i.e., a chain of events initiated by an unexpected
result leading to unnecessary additional testing or treatments) [10–13]. We are now seeing
guidance for clinicians ordering, interpreting, and communicating GS with their patients
[13,14], as well as clinical laboratories supporting the ordering of GS and delivery of reports
that include results that are both clinically actionable and directly relevant to the patients'
indication. While there are some studies exploring the potential for GS to replace traditional
tests in terms of sensitivity, specificity and completeness [15], there are few studies to date
investigating technologies for delivering GS reports under this new paradigm. One group has
developed a web-based platform to automatically generate a clinical report, based on predefined templates, from raw assay results or specified diplotypes [16]. Their framework has
potential to help provide consistent and reproducible reporting while also saving time by
calculating diplo-types and assembling report content. Our work adds to this emerging
literature by taking a user-centered design approach to explore a range of scenarios for
software generating reports from GS for use by clinicians.
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Related to our goal to investigate preferences for content contained in the proposed design of
software are studies of the information needs of clinicians when interpreting GS. These
studies serve as the groundwork to inform the design of software tools [17,18]. While most
of these studies have focused on genetic counselors' information needs, some findings may
be generalized to other clinicians. Genetic counselors have expertise when reviewing GS
reports; therefore, information that they deem necessary should be emphasized when nongenetic expert clinicians are reviewing GS reports. For example, a study surveying genetic
counselors showed that there is a perceived lack of information on the classification system
for variants of unknown significance (VUS) included in laboratory reports, highlighting a
need for improved GS reports to provide transparency [18]. That study also found that
genetic counselors wanted more information, such as patient information, in reports to help
contextualize VUS results [18]. We believe this need for more information about the patient
within laboratory reports can be generalized to other types of clinicians in order to make
patient-specific recommendations. This belief is supported by findings of others indicating
that clinicians desire information available to discuss with the patient [19]. Another study of
interviews with genetic counselors identified specific information needs for risk
communication [17]. Information needs described in that study include clinical patient
characteristics, social and cognitive patient characteristics, and patient motivation and goals
for the genetic counseling session. Those needs may also generalize to non-genetics experts
communicating GS results to patients more broadly, and thus were considered with findings
from phase 1 studies in our proposed software design.

Author Manuscript

While there exist tools and resources for clinical laboratory professionals interpreting and
reporting genetic test results, the design and purpose of these tools varies. One web-based
application, SeqReporter, has been developed for clinical molecular laboratory use for nextgeneration sequencing data analysis [20]. That tool is an automated web-based application
for GS result classification. While it was designed to optimize laboratory reporting, it did not
support the anticipated information needs of non-genetics expert clinical end users. While
the published information provides a starting point, our work gathers additional end-user
input on preferences for interactions with, content contained in and the perceived usability of
the software design by non-genetics clinician experts.
2.1. Methodological Background

Author Manuscript

In order to gather input on the proposed design of software, we used a task-centered system
design (TCSD) protocol in a focus group setting. Other studies have used similar taskcentered approaches to investigate the usability of genetic data interpretation software. For
example, Shyr et al. administered surveys, conducted interviews and performed cognitive
task analyses to assess the usability of a clinical exome analysis software [21]. In another
study a think-aloud, graded-task protocol was used to evaluate the GeneInsight Suite. That
study highlighted a need to provide the most current genetic information [22]. The graded
task protocol facilitated identifying design improvements that could be easily made and
determining larger issues with how the interface was interpreted by end-users. While our
goals to gather input on the design of software were similar, in our modified TCSD protocol,
we did not have participants grade each task they completed. Rather, by conducting our
study in a focus group setting, we allowed for open discussion about proposed software
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design features in order to gather feedback on specific clinical contexts in which those
features would be most useful.

Author Manuscript

In proposing software design characteristics, we explored the inclusion of features that
might be supported by existing clinical system vendors. These included alert messages, and
an HL7 standard, the “Infobutton Standard” [23,24]. The use of infobuttons in electronic
health records (EHRs) is an important method for delivering the most current healthcare
information to clinicians at the point-of-care. The technology lends itself to use with GS
reports, as treatment guidelines and recommendations associated with genetic variation are
ever-improving [25]. Linking to those resources from infobuttons could provide a
mechanism to communicate genomic data and clinical decision support [26]. One study
piloted a pharmacogenomic-based prescribing alert to examine the clinical impact of
embedding infobuttons within an EHR alert [27]. That study offered improvements to make
the infobutton content more useful and increase clinician trust in the alert. Findings from
those studies reinforced our decision to include alert messages and infobuttons in the
proposed design of software capable of providing clinicians with important, current
information with GS results.

3. Materials and Methods
3.1. Recruitment Approach

Author Manuscript
Author Manuscript

Our two-phase study was conducted within a focus group setting. We sent emails to
individuals influenced by the two precision medicine projects at the University of Maryland
School of Medicine. These included 14 TPP/PDMP research team members (clinical
research coordinators, genetic counselors, laboratory professionals), 17 PDMP clinicians
(endocrinology fellows, nurse practitioners, diabetes educators), and 34 TPP clinicians
(cardiology fellows, nurse practitioners, clinical pharmacists). The email was sent with an
information sheet describing the goals of the project. Two weeks later, a second email was
sent to the same pool of potential participants asking for their participation again. A third
email was sent out to interested participants to schedule a focus group. Interested
participants were contacted a fourth and final time to confirm the date and time of the focus
group. A $100 gift card was given to participants. Participants in phase 2 were recruited in
the same fashion and from the same pool of PDMP and TPP clinicians as in phase 1. Those
who participated in phase 1 were allowed to participate in phase 2. This study was reviewed
and judged by the University of Maryland Institutional Review board (IRB) as non-human
subjects research (HP-00061346). At the start of each focus group, participants were given a
participant information sheet. This sheet captured the participant's involvement in TPP and
PDMP projects, years of experience in their profession, gender, and their choice to be
contacted, or not, for future focus groups.
3.2. Phase 1 Data Collection and Analysis
In phase 1, three focus groups were conducted in order to examine existing and anticipated
genetic testing processes among two precision medicine projects (TPP and PDMP). Our
focus group protocol was organized into three topics about genetic test results: laboratory
documentation of genetic test results, making genetic test results available to view in the
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EHR, and notifying the clinician about genetic test results. For each topic, open-ended
questions (e.g., “what is your overall opinion of how genetic test results should be
documented by the testing lab?”) elicited general information followed by more specific
questions and probes (e.g., “what kinds of information do you think should or shouldn't be in
the report?” “when would you want to access information you just mentioned?”). A
moderator and note taker were present at all focus groups, each of which lasted 90–120 min.
Focus group discussions regarding PDMP were modified to cover laboratory test processes
more generally given that data collection occurred prior to the start of genetic testing for that
project. Sessions were audio recorded, transcribed, and analyzed with the aid of Dedoose, a
qualitative research analysis software [28].

Author Manuscript

Two coders (EC, CO) mapped statements made by study participants to terminology
common to user experience and design, and to organizational and business process modeling
heuristics. Our assessment of user experience in phase 1 was focused on usability
(effectiveness, efficiency and satisfaction) and design (missing functionality, problems and
proposed solutions, and desired features). Similar to another study of the usability of clinical
systems [29], we also captured ‘positive’ and ‘negative’ quotes. Positive quotes allowed us
to identify features that satisfied the needs of clinicians and negative quotes allowed us to
identify possible features to improve the use clinical systems for genetic testing processes.
Mappings of statements to usability codes facilitated determining perceived issues with the
use of current clinical systems for genetic testing processes and proposed solutions
acceptable by a range of stakeholders to address those issues. Mappings of statements to
organizational and business process modeling heuristics facilitated determining existing and
anticipated genetic testing processes for documenting, viewing, and notifying individuals
about genetic test results (Appendix B).

Author Manuscript

We completed two analyses of data collected in phase 1. First, we analyzed the data to
understand genetic testing processes of TPP specifically. Findings from that analysis is
described elsewhere [30] and is summarized in the following section. Second, we analyzed
phase 1 data in order to define scenarios and GMA design requirements. Methods and
results from that analysis are described in this manuscript.

Author Manuscript

3.2.1. Summary of Methods and Findings from Previous Work Analyzing
Translational Pharmacogenetics Program Genetic Testing Processes—The
coding team analyzed data from two focus groups (TPP/PDMP research team members and
TPP-related clinicians) in order to document TPP genetic testing processes at the time, and
to propose more streamlined processes enabled by technology. With information gained
from focus groups, we documented TPP genetic testing processes using a Business Process
Model and Notation (BPMN) model [30]. We also performed member checking to verify the
accuracy of our model. In summary, findings indicated a reliance on TPP research team
members to complete tasks that were labor-intensive and potentially error-prone. Findings
also indicated insufficient support and resources to assist clinicians in treatment decisions
with the lab report alone. At the time, important information for making treatment decisions
were provided by the TPP research team in the form of a letter, separate from the lab report
itself. Specific recommendations to enhance TPP genetic testing processes included
reducing the reliance on the TPP research team by establishing a Laboratory Information
J Biomed Inform. Author manuscript; available in PMC 2017 October 01.

Cutting et al.

Page 7

Author Manuscript

Management System (LIMS) for genetic test results that is capable of communicating with
the EHR, and the implementation of clinical decision support (CDS). CDS implementation
could also provide a mechanism to improve access to information for clinicians to make
treatment decisions.

Author Manuscript

3.2.2. Assessing Desired Characteristics for Precision Medicine Scenarios
and Genomic Medicine Assistant Design—We drew from data collected for two
focus groups (TPP-related clinicians and PDMP-related clinicians) to provide evidence for
scenario and software design choices. Scenarios were designed to be relevant to TPP and
PDMP projects and validated with project advisory committee members. Committee
members consisted of experts in clinical genomics, clinical vocabulary standards and clinical
decision support implementation in commercial EHRs (Appendix A). After scenario
validation, we designed project-specific “storybook packets” that included two scenarios,
each of which had associated tasks for accessing GS reports, mockups of those reports and
information resources viewed using GMA. Those notification methods found to be
acceptable by phase 1 study participants were described in both storybook packets. One
team member (EC) proposed initial GMA design mockups informed by participant
recommendations from phase 1 focus groups, the literature describing laboratory report
design principles [31], and model laboratory reports. The packets underwent multiple rounds
revision based upon feedback from the project team prior to finalizing.
3.3. Phase 2 Data Collection and Analysis

Author Manuscript

In phase 2, a modified task-centered system design (TCSD) protocol was applied in a focus
group setting in order to gather feedback from clinicians on a proposed design of the GMA
software. Traditional TCSD involves four main phases: (a) identification of tasks, (b) usercentered requirements analysis, (c) design through use of scenarios or storybooks, and (d)
evaluation of design using walkthrough analyses [32]. In this study we leverage our
understanding of preferences for genetic testing processes from phase 1 analyses in order to
complete TCSD phases a–c. TPP and PDMP clinicians were each asked to complete task
walkthroughs involving two clinical scenarios where GS was performed (see Appendix A
for “Scenarios relevant to the Translational Pharmacogenomics Project” and for “Scenarios
relevant to the Personalized Diabetes Medicine Program”).

Author Manuscript

3.3.1. Administering Storybook Packets for Task Walkthroughs With clinicians
—In phase 2, storybook packets were administered to study participants within a focus
group setting. A moderator and note taker were present at both focus groups, each of which
lasted 90– 120 min. Focus groups were split into two parts, with no discussion during the
first part of the study. Participants were first asked to spend 15–20 min reviewing and
writing down comments or questions about each task/screen presented in the storybook
packet. For the second part, the moderator led a discussion of each task as a group. The
moderator facilitated discussion through the use of probes (e.g., “Is this alert message
informative?”) corresponding to each task (e.g., “Clinician views alert message”). Sessions
were audio recorded, transcribed, and analyzed with the aid of Dedoose, qualitative research
analysis software [28].
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3.3.2. Analysis of Clinician Perceptions of Tasks and Screen Mockups—Two
coders (EC, MB) mapped statements made by study participants to terminology common to
user experience and design, processes for viewing and using the GMA, characteristics of the
GMA design (see Appendix C. Genomic Medicine Assistant Demo Multi-Gene Panel
Laboratory Reports), and roles for different stakeholders (e.g., patient, lab professional,
ordering physician, genetic counselor). Our assessment of user experience was broader in
phase 1 than in phase 2 with the addition of codes for content and usefulness added to our
codebook. Codes for usability and design remained. Codes for organizational and business
processes from phase 1 were replaced by a single code to capture processes for viewing and
using the GMA. Mappings of statements to codes facilitated identifying preferences for and
issues with proposed design features and areas for which there was agreement or
disagreement among focus group participants.

Author Manuscript

3.3.3. Analysis to Characterize Study Participant Views Using System
Usability Scale Survey—In order to characterize the views of our study participants, we
used the System Usability Scale (SUS) survey [33]. The SUS has become a standard of
usability measurement [34]. While other usability evaluation surveys exist [35,36], the SUS
is among the most broadly used and has a number of advantages including its ease of use
with only 10 items rated on a 5-point scale; its comprehensibility given a resultant score
ranging from 0 to 100; and it is “technology agnostic” [33,37]. Participants are asked to
score each item on a scale of one to five that range from Strongly Disagree to Strongly
Agree. Scores were interpreted and analyzed using Sauro's method (30). For each odd
numbered item, one was subtracted from the user response. For each even numbered item,
the user response was subtracted from five. Each user's responses were added up and
multiplied by 2.5 to convert the range of values to 0–100. A score of 68 is an average
usability score. A score above 68 would be considered above average, a score below 68 is
considered below average. Scores were then converted to their percentile rank [33].

Author Manuscript

4. Results
4.1. Study Population
Phase 1 focus groups (three totals) were conducted between December 2014 and February
2015. Phase 2 focus groups with clinicians (two totals) were conducted in May 2015 at
UMMC. Each focus group had a total of four participants (Table 1). With the exception of
one focus group conducted during phase 1 with TPP/PDMP research team members, all
focus groups included 1–2 nurse practitioners and 1–3 physicians. 6 clinicians (nurse
practitioners and physicians) participated in both phases 1 and 2.

Author Manuscript

4.2. Phase 1 Results: Validated Scenarios and Proposed Software Design
The phase 1 analysis uncovered several desired characteristics for scenarios and for the
design of software to support processes for documenting, viewing, and being notified of
genetic and laboratory test results.
4.2.1. Feedback From Clinicians Informing Genomic Medicine Assistant
design—Preferences for documenting and viewing genetic test results informed the design

J Biomed Inform. Author manuscript; available in PMC 2017 October 01.

Cutting et al.

Page 9

Author Manuscript

of the GMA software. Specific clinical preferences for report documentation included
embedding recommendations for the course of treatment based on the patient's results. This
design choice was based primarily upon discussions occurring in the TPP focus group
session. The goal for this would be to reduce the number of steps required for clinicians to
review recommendations for using test results. At the time, recommendations were provided
to clinicians primarily within a letter sent by the study team.

Author Manuscript

TPP and PDMP clinicians had similar preferences for viewing test results. Given that
multiple variants in a single gene or multiple genes may be presented in a single report,
participants expressed a desire for data to be organized by degree of urgency and clinical
significance. We proposed addressing this issue by proposing the use of a multiple tabs to
separate essential and nonessential information in the proposed software design. We also
incorporated a specific recommendation of the TPP clinicians to use to allow for quick
review of the report (e.g., use of the color red to indicate high urgency).
Decisions regarding the organization of content were also informed by model laboratory
reports and recommendations from the literature [31]. Many features are generalizable
across scenarios and are described in Table 3. Potentially generalizable content and content
sections are also illustrated in Fig. 1. Given differences in the availability of information
resources, the inclusion or exclusion of infobuttons varied slightly between scenarios.

Author Manuscript

Focus group participants also reported need for sufficient information to help non-specialist
clinicians explain test results to their patients. TPP clinicians expressed that the information
in current reports was insufficient and that links to external information resources would be
beneficial in their decision-making. PDMP clinicians liked the idea of providing ready
access to electronic resources with GS reports, with a preference for familiar and trusted
resources such as UpToDate® (www.uptodate.com). They made specific suggestions for
access to general information about monogenic diabetes and the ability to print patienttargeted information. These preferences were incorporated in our choice of information
resources, organization of content, and incorporating support for print and email capabilities
into a proposed software design. Other features incorporated into the GMA design included
proposed access to web-based resources using infobuttons and an inbox of all reports
available within the GMA.

Author Manuscript

4.2.2. Validated Scenarios and Proposed Tasks for Reviewing The genomic
Medicine Assistant Design—Notification preferences informed the design of our
scenarios. Study participants indicated a need for improved mechanisms of being notified of
GS and laboratory results. Epic® Systems (Verona, WI) alert and reminder capabilities in
particular were discussed during focus group sessions. Both TPP and PDMP recommended
considering alert messages in the EHR as a preferred mechanism to notify and deliver GS
reports. One suggestion brought up in the TPP focus group specifically was to consider Epic
InBasket messaging. EHR alert and reminder mechanisms (Epic Best Practice Alert [BPA]
and InBasket messages) were therefore incorporated into scenarios as two proposed
mechanisms for notifying clinicians of GS reports. The BPA provides an interruptive form of
clinical decision support notification, while the InBasket provides a more passive form of
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notification where new messages are indicated on a sidebar as the number of new messages
that have been received.
Scenarios are summarized in Table 2. Notification occurred when a clinician opened the
patient chart and methods of notification included Epic BPA and InBasket messages. Both
contained summary information about GS results and a link to view the report in the GMA.
In order to assess both types of notification approaches, the first scenario presented to
cardiology and endocrinology clinicians used BPAs, while the second scenario contained an
InBasket message.

Author Manuscript

Tasks outlined for the scenarios involved a user viewing an EHR alert or reminder message,
clicking on a link within that message to access the GMA software, then viewing the GMA
inbox containing the status of all ordered GS tests and reports. The user opens the preselected GS report and is brought to a lab report Results Tab that contains patient
demographic data, the result, clinical significance, and recommendations. The Results Tab
page also contains infobuttons that link to resources such as OMIM® [47], GeneReviews®
[49], ClinVar [48], supporting literature, and a patient resource. The user then clicks the Test
Information tab, which contains test limitations and other information. See Fig. 1 for an
example of the Results Tab of the report.
4.3. Phase 2 Results: Clinician Perceptions of Tasks and Screen Mockups
Two main themes came out of the phase 2 focus group analysis. First, there were differing
opinions about proposed notification methods. Second, there were user-specific needs for
information and consultation (Table 4).

Author Manuscript

For both of the EHR alert and reminder notification methods we explored, participants
expressed concerns about the frequency of being notified of GS reports (Table 4). For BPAs
specifically, the potential for a high frequency of pop-up BPA alerts was a concern.
Participants agreed that the way the GMA Genetic Test Report tab was structured to provide
optional access to information resources along with concise information summaries could
help to overcome issues with alert fatigue (or desensitization to frequent alerts) [38]. Which
methods of notification were preferred also depended on the scenario. For example, TPP
clinician participants preferred both methods of notification for the pharmacogenomic
sequencing panel report SCN5A result scenario, where as they preferred only one method of
notification for the CYP2C19 result scenario. Study participants also noted that the preferred
method of notification might depend on familiarity with the scenario for using GS results.

Author Manuscript

User-specific needs for information and consultation became evident from comments about
clinicians' familiarity with scenarios, comfort with using GS results and the GMA to make
clinical decisions, and preferences for referral processes (Table 4). Participants explained
that confidence with using the GMA to make clinical decisions and their preferred referral
processes may differ for a non-specialized primary care provider (PCP) who may be
unfamiliar with the GMA and/or GS results. Many participants agreed that they would seek
consultation from a genetics or pharmacogenetics specialist after viewing the GS report.

J Biomed Inform. Author manuscript; available in PMC 2017 October 01.

Cutting et al.

Page 11

4.4. Phase 2 Results: Design Revision Recommendations and Perceptions of Usability
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Study participants offered recommendations to improve the navigation of the software to be
more intuitive and the content more easily and quickly understood (Table 5). These included
specific content improvements such as more clearly defining certain phenotypes. One
important recommendation was to add a resource to view evidence summaries regarding the
clinical utility of the data such as supporting clinical trials. Participants also perceived the
GMA design to be usable with scores ranging from 72.5 to 95 out of 100 on the SUS Survey.
These scores representing the perceptions of our study participants, indicated an above
average usability score of the GMA.

5. Discussion
Author Manuscript

We have proposed a design for the Genomic Medicine Assistant (GMA) software for
generating a report from GS data and provide resources to orient clinicians when viewing
and interpreting results. In phase 1 of our study, focus group participants offered insights
into the complex reporting process of genetic test results within two precision medicine
programs (TPP and PDMP). Key areas of improvement were identified and considered when
defining scenarios and design features for the GMA. In phase 2 we assessed the GMA software design by conducting focus groups and task walkthroughs with clinical end-users
(physicians and nurse practitioners). Major findings we identified were the existence of (a)
differing opinions regarding preferred methods of notification and (b) user-specific needs for
information and consultation.

Author Manuscript

Familiarity with a technology can assist with its integration into everyday routines. To
bolster clinician familiarity with information provided in the GMA, clinician training and
educational programs may be effective. For example, one study piloted a “Genome Report”
containing whole genome sequencing results with non-geneticist physicians. They found
that users viewed the report initially as daunting, but noted that as they became more
familiar with the report, they would be able to better manage subsequent reports [39]. In our
study, while familiarity with genetic test results differed between clinicians involved in our
two precision medicine programs, there were common preferences for information. For
example, regardless of previous experience and education about GS described in our
scenarios, many participants agreed that they would likely seek consultation from a genetics
or pharmacogenetics specialist after viewing the test report.

Author Manuscript

In addition, participants made several recommendations to improve the proposed design of
the GMA that can serve as design principles for other pursuing similar efforts. Focus group
participants reported a desire for information to support more in depth understanding of GS
results. Addressing this desire would need to be considered with care given findings from
others that using too much bioinformatics or genetics jargon causes confusion [21]. In
addition, while actual navigation of the GMA software interface could not be tested during
our task walkthroughs, participants still proposed several areas to improve (Table 5).
Toward improving the likelihood of successful integration with busy healthcare
environments, we employed user-centered design approaches to understand genetic testing
workflow processes and design preferences in order to understand points where technology
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could help support those processes (see “Summary of Findings from Analyzing
Translational Pharmacogenetics Program Genetic Testing Processes” and [30]) and to
provide evidence for scenario and software design choices. We found that the documentation
of GS results by multiple individuals, at different points in the testing process, and into
independent locations can potentially lead to the incorrect communication of a result. We
therefore proposed mechanisms for clinical decision support notification in our scenarios
and proposed design features for documenting and viewing GS reports with potential to
mitigate some of those issues. Overall the proposed scenarios (Table 2) and GMA design
features (Table 3) were well accepted by our study participants. Preferences for notification
by EHR alerts or reminders, however, may depend in part on familiarity with GS results and
urgency of the scenarios. For example, for GS results that cardiology participants' were less
familiar with, they preferred both BPA and InBasket notifications. With CYP2C19 test
results, for which they were more familiar, the cardiology participants' preferred InBasket
notifications.
5.1. Limitations and Future Directions

Author Manuscript

We employed a user-centered design approach with the aim of designing software that fits
within current ways of working (i.e., GS reporting processes that are similar to current
laboratory test delivery processes). There are some processes for GS reporting, however, that
are distinct from other types of laboratory tests such as the need to support mechanisms for
continually updating and improving genetic information. Our proposed design feature to
embed within GS reports links to external references and to continually updated genomic
knowledge bases such as ClinVar [40] would partially supports such mechanisms. The
scenarios we present in this work, however, were for the delivery of results at one point in
time, and do not explore potential changes to interpretations over time. One technology
exploring mechanisms to provide updated interpretations of GS results is GeneInsight,
whose processes have been shown to greatly improve the probability that users receive
updated variant information [41]. Complementing that work would be research to better
understand approaches to notify clinicians of updates to GS findings and interpretations.
There is potential to draw from approaches in human factors engineering to analyze complex
work systems [42,43]. Approaches in contextual inquiry in particular may be used in order
to design technology to support current work systems, or to design new ways of working
that are well supported by technology [44].

Author Manuscript

Another area for further exploration is scenarios for the return of incidental findings
unrelated to the indication for testing. This work explored a scenario related to TPP project
for the return of a potential incidental finding upon ordering a pharmacogenomic sequencing
panel test for another purpose. Of note is that the scenario was highly exploratory and not
based on current standards of care. While others are exploring similar scenarios for returning
GS results with healthy individuals [9], current practice recommendations do not support GS
for that purpose [45].
Some challenges brought up in phase 1 focus groups could not be addressed directly in the
design of the GMA. For example, a clear need identified by participants was to improve the
communication between laboratory systems and the EHR. Focus group participants also
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reported that some processes for notifying clinicians of genetic test results do not notify the
correct members of the care team of an available test result in the TPP project [30]. In both
instances, solutions for these needs were beyond the scope of this project. These are however
broader implementation challenges that will be addressed in the respective TPP and PDMP
projects.
While our prototype can provide a starting point for exploring scenarios for the reporting of
multi-gene sequencing test results, further research is needed to determine applicability to
other scenarios and healthcare organizations. Future studies would benefit from gathering
feedback on multiple design concepts in order identify the best solution for different
environments. In addition, usability studies where individuals are able to interact directly
with a prototype system may help users' understanding of the GMA application.

Author Manuscript

Furthermore, mechanisms to improve the communication between laboratories and
clinicians will be important. As we found in our assessment of TPP genetic testing
processes, laboratory processes for preparing the report are vital for the delivery of results.
The communication between clinicians and laboratories becomes increasingly complex
when GS is involved. Multiple factors now play a part in this communication and should be
considered when building such a connection. These include informed consent, quality of
testing, regulations of the testing laboratory, and most importantly, interpretation of results
[46]. While the GMA provides a framework for delivering reports to clinicians, laboratory
and genetics professionals will continue to guide the development of content for inclusion of
GS reports and the identification of appropriate timing for delivering reports to clinicians.

Author Manuscript

In addition to these findings, study participants perceived the GMA design to be usable and
offered numerous design and content recommendations to further improve its look and feel
(Table 5). Participant preferences for information resources and organization of content from
the first phase of the study were incorporated in the prototype software design presented
during the second phase. Above average perceptions of usability were therefore
unsurprising. Overall design principles resulting from our study can be incorporated into
software applications that support the delivery of GS reports.

6. Conclusion

Author Manuscript

We employed a user-centered software design approach in a focus group setting in order to
facilitate gathering rich contextual information from a diverse group of stakeholders
potentially impacted by the delivery of multi-gene sequencing panel (GS) reports relevant to
two precision medicine programs at the University of Maryland Medical Center. Our
evaluation of the genetic testing processes facilitated identifying preferred mechanisms for
clinicians to be notified of results and preferred information resources to support interpreting
results. Notification by EHR alerts and reminders were explored within scenarios for
ordering and delivering GS reports. Preferences for notification, information and
consultation from genetics specialists appeared to depend upon previous experience and
education about the GS described in scenarios. Despite familiarity with some aspects of the
scenarios, many of our participants agreed that they would likely seek consultation from a
genetics specialist after viewing GS reports. Findings illustrate a need to support customized
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notification approaches, user-specific information, and access to genetics specialists with GS
reports. Design principles from this work can be incorporated into software applications that
deliver GS reports. Our user-centered approach to conduct this assessment and the specific
input we received from clinicians may also be relevant to others working on similar projects.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.

Results tab features. This example shows a pharmacogenomic sequencing panel report.
Note: this image was modified to illustrate the generalizable content sections and features
including tabs and infobuttons embedded in the demo. For screenshots of the Genomic
Medicine Assistant demo see Appendix C.
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Table 1
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Demographic Information collected about focus group participants: Gender, specialty,
years of experience
Characteristics

N (%)

Gender
Female

13 (65)

Male

7 (35)

Study
Study 1

12 (60)

Study 2

8 (40)

Profession

Author Manuscript

Clinical Pharmacist

1 (5)

Physician (Fellow)

13 (65)

Nurse practitioner

2 (10)

TPP/PDMP research team (clinical research coordinators)

3 (15)

TPP/PDMP research team (laboratory professionals)

1 (5)

Clinical specialty
Cardiology

8 (40)

Endocrinology

8 (40)

NA

4 (20)

Years of experience (mean, range)

6.7, 1–35
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Table 2

Summary of scenarios

Author Manuscript

Lab report in the GMA

When opening a new encounter, the healthcare provider is notified…

TPP Scenario 1: BPA notification of a
pharmacogenomic sequencing panel report
(CYP2C19)

…that their patient is a carrier of a genetic variant that causes a reduction in the ability to
metabolize clopidogrel. The message contains a link to view the lab report in the GMA

TPP Scenario 2: InBasket notification of a
pharmacogenomic sequencing panel report
(SCN5A)

…that their patient is a carrier of a pathogenic variant in the SCN5A gene relevant to
Brugada Syndrome (an incidental finding). The message contains a link to view the lab
report in the GMA

PDMP Scenario 1: BPA notification of a
monogenic diabetes sequencing panel report
(HNF1A)

…that their patient has a result consistent with a diagnosis of a genetic form of diabetes
(MODY3) caused by a mutation in HNF1A. The message contains a link to view the lab
report in the GMA

PDMP Scenario 2: InBasket message
notification of a monogenic diabetes
sequencing panel report (HNF1A)

…that their patient has a result consistent with a diagnosis of a genetic form of diabetes
(MODY3) caused by a mutation in HNF1A. The message contains a link to view the lab
report in the GMA
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Table 3

Proposed genomic medicine assistant software design features

Author Manuscript

Deign feature

Description

Screens
Inbox for test reports

This screen contains sortable patient demographic information and the test report status for quick
selection of reports

Results tab

This screen contains patient demographic information, test indication, clinically relevant variant
results, results interpretation, and recommendations

Test Information tab

This screen contains information about the test method and limitations

Infobuttons

Author Manuscript

Gene (all scenarios)

This button opens a new window that displays a gene resource (e.g., OMIM [47], a resource that
provides information about human genes and genetic phenotypes, including supporting references to
confirm genephenotype relationships)

Variant information (all scenarios)

This button opens a new window that displays a gene variant resource (e.g., ClinVar [48], a resource
provides information about the variant identified and the classification of the variant)

Clinical significance (TPP scenario 2
and PDMP scenarios) [NOTE: this
button is not shown in Fig. 1]

This button opens a new window that displays a resource to assist with assessing clinical significance
resource (e.g., GeneReviews [49], a resource provides information on genetic diseases, focusing on
clinically relevant and medically actionable information on the diagnosis, management, and genetic
counseling of patients and families with specific inherited conditions)

Evidence (all scenarios)

This button opens a new window that lists citations or presents a resource that synthesizes evidence to
support interpretations and recommendations included in the laboratory report

Patient resource (all scenarios)

This button opens a new window that displays a patient resource (e.g., Genetics Home Reference [50],
a resource that contains patient-friendly information about the gene tested and disease-associated
information)

Author Manuscript
Author Manuscript
J Biomed Inform. Author manuscript; available in PMC 2017 October 01.

Cutting et al.

Page 22

Table 4

Phase 2 focus group excerpts that support major themes

Author Manuscript

Theme

Excerpts

Differing opinions about
notification methods

“I'm personally not a fan, that [the alert] needs to be closed. […] It stops what you're doing. It will do nothing
but aggravate providers” –Cardiology Fellow, scenario 1
“ At the end of the day, […] you're going through a ton of stuff and you just see words and words and words,
and word. So you have that danger [of alert fatigue] – I'm just going to breeze through that” – Endocrinology
Fellow, scenario 3
“ I wouldn't want a box to pop up and stop what you're doing every time, but if the person is on Plavix and has
any test that says they're a poor metabolizer, they should at least be noted on the side – like a beacon,
something that's alerting you to it without actually stopping what you're doing.” –Cardiology clinician,
scenario 1
“I would probably do both [methods of notification]. I think the problem is this is – this is potentially important
information…for the physician” – Cardiology clinician, scenario 2

More information needed to
support understanding

Author Manuscript

“At least having some background on that [the content for clopidogrel poor metabolizers] to get what it means
[to “effectively metabolize”] …. That [the common variants table] actually might be a little bit vague for a
provider who's not familiar with the test.…It's a small change, but it may make a difference for a lot of people
that don't understand the test well…. It adds a degree of uncertainty”–Cardiology clinician, scenario 1
“[…] what if in the variants table where it says ‘clinical significance’, that column, if you say ‘strong’ –
[where] it says ‘pathogenic variant in gene associated with MODY 3.’ What if you [also] put a [classification
of pathogenicity] or something, just so you know how much evidence backs it up.” –Endocrinology clinician,
scenario 3

Differences in user's
decisions to refer to
specialist

“ […] I would explain and say I don't have all the information. What I could tell you is this… but I think we're
going to a genetic – for a genetic consultation is probably in the best interest.” – Cardiology clinician, scenario
2
“I think the reason to get a genetic person involved is not so much just for the patient but for family members
as well, because they're going to have a lot of other questions, regarding ‘what about my children’… and I
think that's going to be something that the genetics people would have to sort out for you.”– Cardiology
clinician, scenario 2

Information needed within
the GMA may differ based
on the user

“I still think the PCPs wouldn't be comfortable to [make a clinical decision] and that's not surprising.” –
Endocrinology clinician, scenario 3
“I mean, based on [the resources provided] I would make a decision” – Cardiology clinician, scenario 1
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Table 5

Phase 2 focus group design recommendations

Author Manuscript

Timing and navigation recommendations
•

Alert and reminder messages:
– Improve the visibility of the alert/reminder message link that would bring the user to the GMA
software
– Provide with the alert/reminder message, an option to refer the patient to a genetics professional

•

Throughout the software:

•

Inbox:

– Use mouse-overs to display definitions and spell-out acronyms

– Provide support to archive reports, rather than to delete reports
– Provide support to indicate that a report has been reviewed
– Use color to indicate the status of a report (e.g., indicate that a final report is available to view with the
color green)

Author Manuscript

– Include a “Result” column that shows a short description of the result
•

Results tab:
– Make links to resources imbedded in the text more visible (e.g., UpToDate® [51] in the Monogenic
Diabetes Sequencing Panel - Results Page (HNF1A), see Appendix C, Fig. C.5)
– Format the “Evidence” button bibliography to include the abstract of references

Content recommendations
•

Alert and reminder messages:
– Include with generic drug names, the commercial names in parentheses
– Consider the order of treatment alternatives (e.g., Prasurgrel was recommended to be listed first in the
TPP focus group)
– Consider including the same recommendation on the “Recommendations” section of the lab report as
in the alert and reminder messages

Author Manuscript

•

–

TPP example: Add contraindications for prescribing alternative medications
included in the “Recommendations” section to the alert message

–

PDMP example: Introduce link to UpToDate® [51] in the “Interpretation Summary”
section earlier, possibly in the alert message

Results tab
– Include with the “Evidence” button bibliography, citations from clinical studies

•

Pharmacogenomic Sequencing Panel Report (CYP2C19):
– Bring table of common variants to Results tab [NOTE: this was incorporated into the demo report, see
Appendix C, Fig. C.1]
– Define interpretation categorizes (e.g., It was recommended to include quantitative measures of
decreased metabolism for poor metabolizers)

•

Monogenic Diabetes Sequencing Panel (HNF1A):
– “Supporting literature” button should be called “Evidence” or “References” to minimize confusion
about the type of information provided. [NOTE: this was incorporated into the demo reports shown in
Appendix C]
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